Mesalamine and Ipratropium bromide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Mesalamine (mesalamine) and Ipratropium bromide (ipratropium bromide). Common drug interactions include alanine aminotransferase increased among females and bronchitis among males.

The phase IV clinical study analyzes what interactions people have when they take Mesalamine and Ipratropium bromide. It is created by eHealthMe based on reports of 22 people who take the same drugs from the FDA, and is updated regularly.

What is Mesalamine?

Mesalamine has active ingredients of mesalamine. It is often used in ulcerative colitis. eHealthMe is studying from 28,053 Mesalamine users. Check the latest studies of Mesalamine.

What is Ipratropium bromide?

Ipratropium bromide has active ingredients of ipratropium bromide. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 17,965 Ipratropium bromide users. Check the latest studies of Ipratropium bromide.



On Jul, 19, 2026

22 people who take Mesalamine and Ipratropium bromide together, and have interactions are studied.

Mesalamine and Ipratropium bromide drug interactions.

What are the common drug interactions of Mesalamine and Ipratropium Bromide, by gender? *:

female:

  1. Alanine aminotransferase increased
  2. Blood alkaline phosphatase increased
  3. Gamma-glutamyltransferase increased
  4. Oedema peripheral (superficial swelling)
  5. Acidosis (build-up of carbon dioxide in the blood)
  6. Activated partial thromboplastin time prolonged
  7. Acute respiratory failure
  8. Amblyopia (lazy eye)
  9. Asthenia (weakness)
  10. Bacterial culture positive

male:

  1. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  2. Sinusitis (inflammation of sinus)
  3. Clostridium difficile colitis (inflammation of colon by clostridium difficile bacteria infection)
  4. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
  5. Dehydration (dryness resulting from the removal of water)
  6. Haematocrit decreased
  7. Haemoglobin decreased
  8. Hypersensitivity
  9. Ischaemia (insufficient supply of blood to an organ, usually due to a blocked artery)
  10. Lung infection

What are the common drug interactions of Mesalamine and Ipratropium Bromide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Acidosis (build-up of carbon dioxide in the blood)
  2. Activated partial thromboplastin time prolonged
  3. Bacterial culture positive
  4. Bronchopneumonia (inflammation of the lungs, arising in the bronchi or bronchioles)
  5. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  6. Hypotension (abnormally low blood pressure)
  7. International normalised ratio increased
  8. Malaise (a feeling of general discomfort or uneasiness)
  9. Mycobacterium avium complex infection
  10. Oedema (fluid collection in tissue)

50-59:

  1. Hyperglycaemia (high blood sugar)
  2. Hypotension (abnormally low blood pressure)

60+:

  1. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  2. Sinusitis (inflammation of sinus)
  3. Bundle branch block left (absence of transmission of electric impulses from the atrioventricular (av) bundle of his to the left ventricle)
  4. Cardiac disorder
  5. Clostridium difficile colitis (inflammation of colon by clostridium difficile bacteria infection)
  6. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
  7. Dehydration (dryness resulting from the removal of water)
  8. Gamma-glutamyltransferase increased
  9. Haematocrit decreased
  10. Haemoglobin decreased

What are the existing conditions these people have? *

  1. Immunodeficiency Common Variable: 8 people, 36.36%
  2. Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 4 people, 18.18%
  3. Infection: 2 people, 9.09%
  4. Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 2 people, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Mesalamine and Ipratropium bromide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Mesalamine and Ipratropium bromide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Mesalamine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Ipratropium bromide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Mesalamine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ipratropium bromide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on mesalamine and ipratropium bromide (the active ingredients of Mesalamine and Ipratropium bromide, respectively), and Mesalamine and Ipratropium bromide (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: